PEG minocycline-liposomes ameliorate CNS autoimmune disease

PLoS ONE

Volumn 4, Issue 1, 2009, Pages

  Hu, Wei ^a   Metselaar, Josbert ^b   Ben, Li Hong ^a   Cravens, Petra D ^a   Singh, Mahendra P ^a   Frohman, Elliot M ^a   Eagar, Todd N ^a,c   Racke, Michael K ^d   Kieseier, Bernd C ^e   Stüve, Olaf ^a,c,e,f  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b UTRECHT UNIVERSITY   (Netherlands)

^c UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^d OHIO STATE UNIVERSITY   (United States)

^e HEINRICH HEINE UNIVERSITY   (Germany)

^f VA NORTH TEXAS HEALTH CARE SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GELATINASE B; LIPOSOME; MACROGOL; MINOCYCLINE; ANTIINFECTIVE AGENT; MACROGOL DERIVATIVE; MATRIX METALLOPROTEINASE;

ALLERGIC ENCEPHALOMYELITIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG DOSAGE FORM COMPARISON; DRUG MECHANISM; DRUG STABILITY; ENZYME INHIBITION; HUMAN; HUMAN CELL; IN VITRO STUDY; LEUKOCYTE COUNT; LEUKOCYTE MIGRATION; MALE; MOUSE; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; SPLEEN CELL; ANIMAL; C57BL MOUSE; DISEASE MODEL; DRUG ANTAGONISM; FEMALE; IMMUNOLOGY; METABOLISM;

ANIMALIA;

ANIMALS; ANTI-BACTERIAL AGENTS; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; FEMALE; HUMANS; LIPOSOMES; MATRIX METALLOPROTEINASE 9; MATRIX METALLOPROTEINASES; MICE; MICE, INBRED C57BL; MINOCYCLINE; NERVOUS SYSTEM AUTOIMMUNE DISEASE, EXPERIMENTAL; POLYETHYLENE GLYCOLS;

EID: 58349110811     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0004151     Document Type: Article

References (25)

1. Zamvil SS, Steinman L (1990) The T lymphocyte in experimental allergic encephalomyelitis. Annu Rev Immunol 8: 579-621.
2. Leppert D, Waubant E, Galardy R, Bunnett NW, Hauser SL (1995) T cell gelatinases mediate basement membrane transmigration in vitro. J Immunol 154: 4379-4389.
3. Yong VW, Power C, Forsyth P, Edwards DR (2001) Metalloproteinases in biology and pathology of the nervous system. Nat Rev Neurosci 2: 502-511.
4. Leppert D, Waubant E, Burk MR, Oksenberg JR, Hauser SL (1996) Interferon beta-1b inhibits gelatinase secretion and in vitro migration of human T cells: a possible mechanism for treatment efficacy in multiple sclerosis. Ann Neurol 40: 846-852.
5. Stuve O, Dooley NP, Uhm JH, Antel JP, Francis GS, et al. (1996) Interferon beta-1b decreases the migration of T lymphocytes in vitro: effects on matrix metalloproteinase-9. Ann Neurol 40: 853-863.
6. Stuve O, Chabot S, Jung SS, Williams G, Yong VW (1997) Chemokine-enhanced migration of human peripheral blood mononuclear cells is antagonized by interferon beta-1b through an effect on matrix metalloproteinase-9. J Neuroimmunol 80: 38-46.
7. Popovic N, Schubart A, Goetz BD, Zhang SC, Linington C, Duncan ID (2002) Inhibition of autoimmune encephalomyelitis by a tetracycline. Ann Neurol 51: 215-223.
8. Brundula V, Rewcastle NB, Metz LM, Bernard CC, Yong VW (2002) Targeting leukocyte MMPs and transmigration: minocycline as a potential therapy for multiple sclerosis. Brain 125: 1297-1308.
9. Nessler S, Dodel R, Bittner A, Reuss S, Du Y, Hemmer B, Sommer N (2002) Effect of minocycline in experimental autoimmune encephalomyelitis. Ann Neurol 52: 689-690.
10. Metselaar JM, Storm G (2005) Liposomes in the treatment of inflammatory disorders. Expert Opin Drug Deliv 2: 465-476.
11. Kieseier BC, Kiefer R, Clements JM, Miller K, Wells GM, et al. (1998) Matrix metalloproteinase-9 and -7 are regulated in experimental autoimmune encephalomyelitis. Brain 121(Pt 1): 159-166.
12. Stuve O, Bennett JL, Hemmer B, Wiendl H, Racke MK, et al. (2008) Pharmacological treatment of early multiple sclerosis. Drugs 68: 73-83.
13. Yong VW, Wells J, Giuliani F, Casha S, Power C, Metz LM (2004) The promise of minocycline in neurology. Lancet Neurol 3: 744-751.
14. Keilhoff G, Langnaese K, Wolf G, Fansa H (2007) Inhibiting effect of minocycline on the regeneration of peripheral nerves. Dev Neurobiol 67: 1382-1395.
15. Kloppenburg M, Breedveld FC, Terwiel JP, Mallee C, Dijkmans BA (1994) Minocycline in active rheumatoid arthritis. A double-blind, placebo-controlled trial. Arthritis Rheum 37: 629-636.
16. Harel L, Amir J, Livni E, Straussberg R, Varsano I (1996) Serum-sickness-like reaction associated with minocycline therapy in adolescents. Ann Pharmacother 30: 481-483.
17. Matsuura T, Shimizu Y, Fujimoto H, Miyazaki T, Kano S (1992) Minocycline-related lupus. Lancet 340: 1553.
18. Davies MG, Kersey PJ (1989) Acute hepatitis and exfoliative dermatitis associated with minocycline. BMJ 298: 1523-1524.
19. Pelletier F, Puzenat E, Blanc D, Faivre B, Humbert P, Aubin F (2003) Minocycline-induced cutaneous polyarteritis nodosa with antineutrophil cytoplasmic antibodies. Eur J Dermatol 13: 396-398.
20. Langevitz P, Livneh A, Bank I, Pras M (2000) Benefits and risks of minocycline in rheumatoid arthritis. Drug Saf 22: 405-414.
21. Metz LM, Zhang Y, Yeung M, Patry DG, Bell RB, et al. (2004) Minocycline reduces gadolinium-enhancing magnetic resonance imaging lesions in multiple sclerosis. Ann Neurol 55: 756.
22. Rouser G, Fkeischer S, Yamamoto A (1970) Two dimensional then layer chromatographic separation of polar lipids and determination of phospholipids by phosphorus analysis of spots. Lipids 5: 494-496.
23. Stuve O, Youssef S, Slavin AJ, King CL, Patarroyo JC, et al. (2002) The role of the MHC class II transactivator in class II expression and antigen presentation by astrocytes and in susceptibility to central nervous system autoimmune disease. J Immunol 169: 6720-6732.
24. Stuve O, Youssef S, Weber MS, Nessler S, von Budingen HC, et al. (2006) Immunomodulatory synergy by combination of atorvastatin and glatiramer acetate in treatment of CNS autoimmunity. J Clin Invest 116: 1037-1044.
25. Gocke AR, Cravens PD, Ben LH, Hussain RZ, Northrop SC, et al. (2007) T-bet regulates the fate of Th1 and Th17 lymphocytes in autoimmunity. J Immunol 178: 1341-1348.